While Juno Therapeutics Inc (NASDAQ:JUNO) rides a positive tide following an abstract release from The American Society of Hematology (ASH), shares are rising …
In a research report released Thursday, FBR analyst Edward White reiterated an Outperform rating on shares of Juno Therapeutics Inc (NASDAQ:JUNO) with a price …
Juno Therapeutics Inc (NASDAQ:JUNO) shares rose nearly 4% today after the journal Science Translational Medicine published a paper that showed encouraging results for patients …
In a paper published in Science Translational Medicine,researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with …
In a research report released yesterday evening, BTIG analyst Dane Leone initiated coverage on shares of Juno Therapeutics Inc (NASDAQ:JUNO) with a Sell rating …
Merrimack Pharmaceuticals Inc Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares closed down over 6% Friday, after the cancer drug maker reported second-quarter results, with net Onivyde sales …
In a research report released Friday, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Juno Therapeutics Inc (NASDAQ:JUNO), while slashing …
Juno Therapeutics Inc (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, announced today that it …
Analyst Michael Schmidt from Leerink Swann shared his thoughts on Juno Therapeutics Inc (NASDAQ:JUNO), following its $10 million acquisition of RedoxTherapies. In addition to …
